The tweet was deleted by the author.
But we saved everything 🙂.
Agenus announced new phase 2 clinical data at ESMO26 showing that 83 percent of patients with locally advanced dMMR colon cancer who received BOT and BAL before surgery achieved a major pathologic response.
Additionally, 72 percent of patients reached a pathologic complete response following the treatment. The results highlight progress in treatment options for this specific subtype of colon cancer.
View post on X Loading...
Agenus recently secured Armenia’s first marketing authorization for its BOT plus BAL therapy in adults with previously treated MSS mCRC, according to a company announcement. The company is also scheduled to report its third quarter 2026 financial results on November 5 before U.S. market open, as stated in a prior statement. These updates reflect Agenus’s ongoing activity in both clinical development and regulatory milestones.